You Are Here: Home > Treatment > Medication > Biosimilars
Biologics and Biosimilars

Biologics and Biosimilars

Biologic drugs represent a major step forward in treating inflammatory forms of arthritis such as rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. These advanced medications are produced through complex processes involving living organisms, and are designed to interfere with the body's inflammatory response in various ways.

As original biologics come off patent, new medications called biosimilars (sometimes called subsequent entry biologics or SEBs) are now available in Canada, offering additional treatment options for Canadians with inflammatory arthritis.

For detailed information about particular medications, see our Arthritis Medication Guide.

The Arthritis Society’s position paper (pdf) addresses the place of biosimilars in the range of approved treatment options in Canada, to help inform patients, physicians, drug plan providers and regulators. For more on this and our other advocacy efforts, visit our Advocacy page.

Resources

Biologics (including biosimilars) are powerful but complex medications. These resources are designed to help you better understand these drugs, how they are different from other traditional drugs, how they work, and what you need to be aware of as you consider your treatment options.

Inflammatory Arthritis Medications Explained


This video gives you a quick walk-through of the different categories of treatment typically used to address arthritis inflammation, how they are different, and gives particular attention to the role of biologics and biosimilars.

What's in a Name? (Biosimilars explained)

Biosimilars Infographic
This resource provides an at-a-glance review of the things you need to know about biosimilars.
Download Infographic (jpg)

Additional Resources

Biosimilar Focus Group Report 

Learn what Canadians think of biologics and biosimilars, their hopes and concerns, and the things they are looking for from the treatment decision process with their physicians.

Position Paper: Access to Medication – Biologics and Biosimilars

The Arthritis Society’s position on biologic medications, the implications of biosimilars, and what people with inflammatory arthritis, physicians and policy makers need to know.